Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BAX | Q07812 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9645412 | 0.82 | TTR (0.65) | ALOX5TTRLTA4HNR1H2BAX | |
| SCHEMBL7191128 | 0.79 | CA2 (0.50) | LTA4HNR1H2BAXMEN1USP2 | |
| SCHEMBL7191617 | 0.78 | TTR (0.73) | TTRGAA | |
| SCHEMBL7196265 | 0.77 | KMT2A (0.43) | CYP1A2TTRLTA4HNR1H2BAX | |
| SCHEMBL27735401 | 0.75 | LTA4H (0.71) | CYP1A2LTA4HNR1H2BAXTYR | |
| SCHEMBL7183343 | 0.75 | LTA4H (0.46) | CYP1A2LTA4HNR1H2BAXMEN1 | |
| SCHEMBL7535559 | 0.74 | KMT2A (0.44) | CYP1A2MEN1GAAKMT2A | |
| SCHEMBL2859448 | 0.74 | CYP3A4 (0.50) | CYP1A2LTA4HNR1H2BAX | |
| SCHEMBL2198518 | 0.73 | MAOB (0.44) | ALOX5TTRTYRMEN1KMT2A | |
| SCHEMBL10902147 | 0.73 | TTR (0.54) | ALOX5TTRLTA4HNR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304924-A2 | COMPOSITIONS FOR REPELLING CRAWLING INSECTS | Bayer Aktiengesellschaft (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20020094993-A1 | Compositions for repelling crawling insects | S.C. JOHNSON & SON, INC. | 2002-07-18 | — | — | US | disclosed |
| WO-2002005646-A2 | COMPOSITIONS FOR REPELLING CRAWLING INSECTS | S.C. JOHNSON & SON, INC. (US) (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094993-A1 | Compositions for repelling crawling insects | ACHE, DDT, GAP43 | ALOX5 884/4885CYP1A2 1275/4885TTR 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.